BioNTech SE

@BioNTech_Group

Our vision: Harnessing the immune system’s power to turn science into survival. Data Privacy: bit.ly/4fdYEf6 Imprint: bit.ly/3YmtoUr

Mainz, Germany

biontech.com

Replies Reposts Media

BioNTech SE
@BioNTech_Group
Sep 16
Lung cancer is not one disease. Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain. Watch 👇 #LungCancer #CancerResearch
00:00
BioNTech SE
@BioNTech_Group
Sep 14
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer. 🔗 Learn more: bit.ly/4h5DjqL #LungCancer #WCLC26
1
BioNTech SE
@BioNTech_Group
Aug 20
We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer. 🔗 Learn more: bit.ly/4gaKY7W #LungCancer #Oncology #WCLC26 #BioNTech
6
BioNTech SE
@BioNTech_Group
Aug 4
📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: bit.ly/4h9thXn
1
BioNTech SE
@BioNTech_Group
Aug 1
We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more. Explore the many: bit.ly/3TuyK13 #WorldLungCancerDay